April Wilson
Adult Health · Longwood, FLNPI 1396458915
Payments from drug & device makers
Across 134 payments — averaging $20.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$411
- AbbVie$368
- Amgen$347
- Sumitomo Pharma America, Inc.$230
- Takeda Pharmaceuticals U.S.A., Inc.$187
- Boehringer Ingelheim$173
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,746100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 20 | $411 |
| AbbVie | 18 | $368 |
| Amgen | 18 | $347 |
| Sumitomo Pharma America, Inc. | 11 | $230 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $187 |
| Boehringer Ingelheim | 9 | $173 |
| Bayer | 5 | $170 |
| Lilly USA, LLC | 8 | $153 |
| AstraZeneca(2 entities) | 8 | $144 |
| Pfizer | 7 | $130 |
| Exact Sciences | 5 | $107 |
| GSK | 5 | $89 |
| Johnson & Johnson | 2 | $50 |
| Daiichi Sankyo Inc. | 2 | $42 |
| Axsome Therapeutics, Inc. | 1 | $34 |
| Harmony Biosciences LLC | 1 | $30 |
| Idorsia Pharmaceuticals US Inc | 2 | $26 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Abbott | 1 | $19 |
| Blueprint Medicines Corporation | 1 | $13 |
How this compares
$2,746 in reported general payments places this provider in the 80th percentile of 2,237 adult health providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $30,947 |
| JardianceEmpagliflozin | 17 | $18,055 |
| MounjaroTirzepatide | 12 | $12,201 |
| EliquisApixaban | 13 | $9,278 |
| Lagevrio (Eua)Molnupiravir | 16 | $6,330 |
| EdarbiAzilsartan Medoxomil | 12 | $3,000 |
| SynthroidLevothyroxine Sodium | 27 | $2,113 |
| Estradiol | 21 | $1,319 |
| Losartan Potassium | 108 | $1,106 |
| Duloxetine Hcl | 38 | $1,033 |
| Rosuvastatin Calcium | 110 | $947 |
| Raloxifene Hcl | 11 | $899 |
| Gabapentin | 40 | $883 |
| ValacyclovirValacyclovir Hcl | 14 | $866 |
| Atorvastatin Calcium | 79 | $798 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $411 | $30,94727 claims |
| Boehringer IngelheimJardiance | $173 | $18,05517 claims |
| Lilly USA, LLCMounjaro | $153 | $12,20112 claims |
| PfizerEliquis | $130 | $9,27813 claims |
| AbbVieSynthroid | $368 | $2,11327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,237 adult health providers in Florida.
Other adult health in Longwood
- Patricia PagnottaMaitland$441K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
- Jessica MangesClearwater$52K
- Sita SwamyOrlando$49K
- Alejandro Dela CruzOrlando$44K
- Cynthia OteroMaitland$31K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.